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MicroRNAs (miRNAs) regulate the function of several
immune cells, but their role in promoting CD8+ T cell
immunity remains unknown. Here we report that
miRNA-155 is required for CD8+ T cell responses to
both virus and cancer. In the absence of miRNA-
155, accumulation of effector CD8+ T cells was
severely reduced during acute and chronic viral
infections and control of virus replication was
impaired. Similarly, Mir155/ CD8+ T cells were
ineffective at controlling tumor growth, whereas
miRNA-155 overexpression enhanced the antitumor
response. miRNA-155 deficiency resulted in accu-
mulation of suppressor of cytokine signaling-1
(SOCS-1) causing defective cytokine signaling
through STAT5. Consistently, enforced expression
of SOCS-1 in CD8+ T cells phenocopied the miRNA-
155 deficiency, whereas SOCS-1 silencing aug-
mented tumor destruction. These findings identify
miRNA-155 and its target SOCS-1 as key regulators
of effector CD8+ T cells that can be modulated to
potentiate immunotherapies for infectious diseases
and cancer.
INTRODUCTION
CD8+ T cells are essential effectors in immune responses to
intracellular pathogens and cancer (Zhang and Bevan, 2011).
Upon stimulation, antigen-specific CD8+ T cells massively
expand and differentiate into inflammatory cytokine producing,
cytolytic T cells able to eliminate virally infected or transformed
cells. As the antigen is cleared, the majority of specific CD8+
effector T cells die (Marrack and Kappler, 2004), whereas only
a small number of memory cells survive. The CD8+ T cell742 Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc.response is influenced by a series of costimulatory (and inhibi-
tory) ligands and by multiple soluble mediators such as inter-
leukin-2 (IL-2) (Boyman and Sprent, 2012). The latter is essential
for sustaining an efficient effector response, whereas other cyto-
kines such as IL-7 and IL-15 play crucial roles for the survival of
naive or memory T cells (Cui and Kaech, 2010). Several studies
have identified key molecular factors involved in the differentia-
tion from naive to effector CD8+ T cells, but the contribution of
microRNAs (miRNAs) has just begun to be investigated (Almanza
et al., 2010).
miRNAs are a class of small, noncoding RNAs that
impart posttranscriptional gene regulation (Bartel, 2004) through
several mechanisms including translational repression and
messenger RNA (mRNA) degradation (Djuranovic et al., 2011).
They are important in many physiological processes, in carcino-
genesis (Calin and Croce, 2006), and in the immune system (Xiao
and Rajewsky, 2009). Early studies in mice deficient for Dicer, an
RNase III enzyme important for mature miRNA production,
revealed that miRNAs are involved in CD4+ T cell differentiation
and strongly influence CD8+ T cell responses (Muljo et al.,
2005; Zhang and Bevan, 2010). Specific miRNAs were shown
to regulate both lymphocyte development and function. For
instance, miRNA-181a influences thymocyte selection bymodu-
lating the expression of molecules involved in T cell receptor
(TCR) signaling (Li et al., 2007). Moreover, the miRNA-1792
cluster regulates B cell development (Ventura et al., 2008), auto-
immunity, and T helper 1 (Th1) cell differentiation (Jiang et al.,
2011; Xiao et al., 2008).
miRNA-155 is upregulated upon lymphocyte activation
(Haasch et al., 2002) to control cell proliferation and differentia-
tion (O’Connell et al., 2008; Turner and Vigorito, 2008). For
instance, miRNA-155 regulates B cell proliferation, malignancy,
and antibody production, at least in part through inhibition of
activation-induced cytidine deaminase and PU.1 expression
(Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007).
In CD4+ T cells, miRNA-155 has been shown to suppress differ-
entiation of naive cells into Th2 by downregulation of c-Maf, to
promote Th17 cell-mediated inflammation (Kurowska-Stolarska
Figure 1. miRNA-155 Expression Is Regu-
lated at Various Stages of CD8+ T Cell
Differentiation in a TCR-Affinity-Dependent
Manner
(A) Quantification of miRNA-155 in human CD8+
T cells transduced with TCRs of increasing affinity
following TCR stimulation with multimers (n = 3
experiments) as fold increase relative to un-
stimulated clones.
(B) miRNA-155 expression of naive mouse OT-1
T cells stimulated with splenic dendritic cells
pulsed with the natural SIINFEKL (N4) or
weaker SIITFEKL (T4) altered peptide ligand as
relative to day 0 unstimulated cells. Data are
representative for triplicates in one out of two
experiments.
(C) miRNA-155 concentrations in naive, central
memory, and effector CD8+ T cells sorted at day 8
after LCMVWE infection as fold change relative to
naive cells.
(D) Relative miRNA-155 expression in splenic
naive and effector CD8+ T cells sorted from
LCMV-infected mice. Symbols represent indi-
vidual mice and the line is the mean ± SEM.
Data are representative for two independent
experiments. For human BIC expression, also see
Figure S1.
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miRNA-155 Drives the CD8+ T Cell Responseet al., 2011; O’Connell et al., 2010) and to inhibit interferon-gR
(IFN-gR) expression (Banerjee et al., 2010; Martinez-Nunez
et al., 2011). In addition to direct modulation of cytokine receptor
expression, miRNA-155 shapes cytokine signaling in several cell
subsets via downregulation of SMAD2 (Louafi et al., 2010) and
suppressor of cytokine signaling (SOCS-1) (Lu et al., 2009;
O’Connell et al., 2010; Wang et al., 2010). Despite the evidence
for an important role of miRNA-155 in a wide spectrum of im-
mune compartments, it is not known whether this miRNA, which
is highly expressed in antigen-experienced CD8+ T cells (Salaun
et al., 2011), influences CD8+ T cells in vivo. In the present study,
we have investigated the role of miRNA-155 during CD8+ T cell
responses to viral infection, vaccination, and cancer.
RESULTS
CD8+ T Cells Dynamically Regulate miRNA-155
Depending on theMagnitude of TCRStimulation or Their
Differentiation State
The strength of TCR signaling has a major impact on the magni-
tude of CD8+ T cell expansion, but not on their differentiation
(Zehn et al., 2009).We sought to investigate whether the strength
of TCR stimulation affects the expression of miRNA-155 in CD8+
T cells by transducing human CD8+ T cells with variants of a NY-
ESO-1-specific TCR of increasing affinity for its ligand (Derre´
et al., 2008; Schmid et al., 2010). Comparatively, a mutated
low-affinity TCR failed to upregulate miRNA-155 within 48 hr,
whereas TCR variants of higher affinities induced higher levels
of miRNA-155 than the wild-type (WT) (Figure 1A). Thus,
miRNA-155 expression increased in a TCR affinity-dependent
manner in human CD8+ T cells. A similar upregulation wasobserved for the pri-miRNA-155 noncoding RNA transcript,
BIC (see Figure S1 available online). To see whether miRNA-
155 was also regulated in an affinity-dependent manner in
mouse CD8+ T cells, we activated naive OT-1 T cells with splenic
dendritic cells (DC) loaded with the WT peptide SIINFEKL (N4) or
the weaker altered peptide ligand SIITFEKL (T4) (Daniels et al.,
2006). To exclude miRNA-155 contamination from the DCs, we
used Mir155/ DCs, which retain normal antigen-presenting
capabilities (O’Connell et al., 2010). Exposure of OT-1 cells to
the WT natural peptide resulted in a strong upregulation of
miRNA-155, whereas a weaker TCR stimulation by the T4
peptide was less effective (Figure 1B). To assess miRNA-155
regulation in vivo, we analyzed naive (CD62L+CD44–), effector
(CD62L–CD44+) and central memory (CD62L+CD44+) CD8+
T cells following lymphocytic choriomeningitis virus (LCMV)
infection (200 pfu ofWE strain). Compared to their naive counter-
parts, miRNA-155 was strongly upregulated in effector cells and
to a lower extent in central memory CD8+ T cells 8 days postin-
fection (Figure 1C). A more detailed kinetics of miRNA-155
regulation during LCMV infection revealed that numbers of
effector cells peaked on day 6 but stayed low in naive cells (Fig-
ure 1D). These results demonstrate that miRNA-155 is induced in
effector CD8+ T cells depending on the strength of stimulation
and differentiation.
miRNA-155 Promotes the Accumulation of Anti-Viral
Effector and Central Memory CD8+ T Cells
To determine the role ofmiRNA-155 in activatedCD8+ T cells, we
monitored the expansion of effector cells following acute LCMV
WE strain infection in the presence or absence of miRNA-155.
Percentage, number, and phenotype of naive Mir155/ CD8+Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc. 743
Figure 2. miRNA-155 Is Required for Optimal Effector CD8+ T Cell Accumulation and Memory Cell Differentiation during Acute LCMV
Infection
(A) Splenocytes from day 8 infected WT and Mir155/ mice were stained with Kb/LCMV gp33 tetramers and anti-CD8a.
(B) Blood percentages and numbers of CD8+ (upper panels) and gp33 tetramer+ cells (lower panels) on day 8 of infection.
(C) Percentages of CD44hiCD62Llo effector CD8+ T cells gated on lymphocytes in WT and Mir155/ spleen cells (upper) and of gp33 tetramer+ cells within the
CD8+ T cells (lower panel) at days 6 to 8.
(D) Percentages of total CD8+ T cells (left) and CD127+ cells within tetramer gp33+ CD8+ cells (right panel) in blood at given time points.
(E) Percentage of liver CD127hiCD62Lhi tetramer gp33 and np396+ memory cells and (F) IL-2 production upon gp33 peptide restimulation of splenocytes within
IFN-g-positive CD8+ T cells at 3 months past infection. Symbols represent individual mice, and the line is the mean +/ SEM. Representative results of one out of
four (A–C) to two (D–F) independent experiments with three to five mice are pictured. Also see Figure S2.
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miRNA-155 Drives the CD8+ T Cell ResponseT cells in blood and spleen did not differ from those in WT mice
before infection (Figure S2A; data not shown). In contrast, both
percentage and number of total CD8+ T cells, as well as virus
gp33 tetramer specific CD8+ effector T cells, were substantially
reduced in spleen and blood of Mir155/ mice at the peak of744 Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc.the response (Figures 2A and 2B). Following the expansion of
CD44+ effector cells in the blood and spleen from days 6 to 8,
we observed impaired effector CD8+ cell accumulation in spleen,
liver, and blood of Mir155/ mice (Figure 2C; data not shown).
Despite a defect in the magnitude of effector T cell responses,
Figure 3. A Cell Intrinsic Role for miRNA-
155 in Promoting Effector CD8+ T Cells
(A) Congenically marked WT and Mir155/ OT-1
cells were competitively cocultured with peptide-
pulsed dendritic cells, and the ratio of populations
is pictured at indicated time points (left). On day 5,
percentage of trypan blue cells harvested from
either WT orMir155/ cultures was counted (right
graph). Pooled data from three representative
experiments are pictured.
(B) CD8+ T cells fromWT andMir155/mice were
cotransferred into WT or deficient hosts before
LCMV WE infection, and percentages in blood at
day 8 were measured.
(C) A 1:1 mix of WT and Mir155/ splenocytes
was adoptively transferred into Rag2 and IL2Rg
double deficient mice, which were infected with
LCMV WE 2 months after transfer. CD8+ effector
T cell ratios at days 1 and 8 postinfection are
pictured.
(D) Proliferating BrdU-positive splenic CD44hi
CD8+ effector T cells at days 6 and 7 postinfection.
(E and F) At the same time, (E) cells were stained
for the proliferation marker Ki67 (day 7) and (F)
apoptotic cells were identified by AnnexinV stain-
ing. Symbols represent individual mice, and the
line is the mean ± SEM. Representative results
from two (B and C) to three (D–F) experiments are
pictured.
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miRNA-155 Drives the CD8+ T Cell ResponseMir155/ animals were capable of controlling viral replication
and clearing the virus (Figure S2B), as also confirmed by the
lack of CD44 upregulation on adoptively transferred naive
LCMV-specific P14 T cells (Figure S2C). In line with this result,
CD8+ T cells differentiated into phenotypically and functionally
cytolytic effector cells similar to WT cells during LCMV infection
(Figures S2A, S2D, and S2E). Interestingly, circulating T cells in
Mir155/ mice exhibited not only a defect in the expansion at
the peak of the immune response but also a more rapid contrac-
tion compared to WT animals (Figure 2D). Moreover, CD127+
CD62L+KLRG1– memory cells were strongly reduced in the
gp33 and np396 tetramer+ CD8+ T cells in blood, liver, and
spleen ofMir155/mice 3months after infection (Figure 2E; Fig-
ure S2F; data not shown). Consistent with these findings, IL-2
production, a hallmark of central memory cells, was strongly
diminished inMir155/mice after stimulation with gp33 peptide
(Figure 2F; Figure S2F). In this immune memory context, it is of
interest that we observed a deficient CD4+ effector T cell activa-
tion on day 8 of the response inMir155/mice (data not shown).
Altogether, these results demonstrate that miRNA-155 is crucial
for a robust T cell expansion, but not effector functions, as well
as for a memory phenotype response upon an acute LCMV
infection.Immunity 38, 742–7Intrinsic Expression of miRNA-155
in CD8+ T Cells Promotes
Proliferation and Limits Apoptosis
of Effector CD8+ T Cells
To investigate whether the defective
expansion of CD8+ T cells was cell
intrinsic, we cocultured naive WT and
congenic Mir155/ OT-1 CD8+ T cells
together with peptide pulsed dendritic cells and analyzed the
OT-1 cell ratio. After 5 days, WT CD8+ T cells outnumbered
Mir155/ cells and the abundance of dead cells was strongly
increased amongMir155/ T cells (Figure 3A). To assess these
parameters in vivo, we cotransferred equal numbers of congenic
polyclonal WT and Mir155/ CD8+ T cells into either WT or
Mir155/ hosts, which were then infected with LCMV. Despite
the initial low frequency of WT CD8+ T cells transferred in
miRNA-155 ablated hosts (about 1% of CD8+ T cells in blood
before infection), these cells expanded to about 30% of the
CD8+ T cells at the peak of the response. In contrast, the fre-
quency ofMir155/ CD8+ T cells that transferred into WT hosts
decreased upon infection (Figure 3B), clearly demonstrating a
stronger response of WT compared to Mir155/ CD8+ T cells.
When Rag2 and g common (gc) chain deficient hosts were
engrafted with a 1:1 mix of WT and Mir155/ splenocytes,
both populations reached similar frequencies after 2 months,
indicating comparable homeostatic expansion (Figure 3C). How-
ever, following LCMV infection, WT T cells again showed an
advantage in expansion over their Mir155/ counterparts. To
determine the basis for the impaired accumulation of virus-spe-
cific CD8+ T cells in the absence ofmiRNA-155, we pulsed LCMV
infectedWT andMir155/mice with bromodeoxyuridine (BrdU)53, April 18, 2013 ª2013 Elsevier Inc. 745
Figure 4. miRNA-155 Drives Survival of
Effector Cells and Sustains the Anti-Viral
Response in a Chronic LCMV Infection
WT and Mir155/ mice were infected with LCMV
clone 13 and phenotype and expansion of effector
cells was monitored by flow cytometry.
(A) Effector CD44hiCD62Llo within blood CD8+
T cells at indicated time points.
(B and C) At 5 weeks, splenic CD8+ cells were
analyzed for the indicated activation markers and
gp33 tetramer+ cells shown as (B) flow cytometry
dot blots from representative mice and (C) graph
from one representative out of three experiments.
(D) Virus titer and (E) cytokine response upon
stimulation with a peptide cocktail was deter-
mined in the blood at 2 and 3 months after infec-
tion, respectively.
(F) Weight of mice was monitored the first 2 weeks
postinfection. Symbols represent individual mice,
and the line is the mean (C and D). Error bars are
given as ± SEM. Shown are representative results
from one out of two experiments with three to five
mice per group.
Immunity
miRNA-155 Drives the CD8+ T Cell Responseand measured proliferation and apoptosis 4 hr later. We found
that the proliferation of Mir155/ CD44+ effector CD8+ T cells
was decreased compared to WT cells 6 days after infection (Fig-
ure 3D). Additionally, the frequency of proliferating Ki67+ cells
within the CD44+CD62L– effector CD8+ T cells was reduced in
Mir155/ mice (Figure 3E). Finally, we observed an increased
frequency of AnnexinV+ apoptotic cells in Mir155/ compared
to WT effector CD8+ T cells 7 days after infection (Figure 3F).
Altogether, these data demonstrate a cell-intrinsic role of
miRNA-155 in the proliferation and survival of effector CD8+
T cells in response to LCMV infection, but not for homeostatic
expansion in lymphopenic hosts.
miRNA-155 Is Crucial for Effector CD8+ T Cell
Accumulation and Virus Control in Chronic LCMV
Infection
On the basis of the strong impairment of effector CD8+ T cell
accumulation in low dose LCMV infection, we asked how
Mir155/ mice would respond to high dose and long-lasting746 Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc.antigen exposure, which characterizes
chronic infections and cancer. Mice
were inoculated with 2 3 106 pfu of
LCMV clone 13, causing a chronic infec-
tion for several weeks (Moskophidis
et al., 1993; Salvato et al., 1991).Whereas
WTmice mounted a robust effector CD8+
T cell response with high percentages of
CD44+CD62L– effector cells that were
maintained over time, Mir155/ mice
progressively lost effector CD8+ T cells
(Figure 4A). Interestingly, the remaining
CD44+ cells in spleen showed high
CD127 and CD62L expression, reminis-
cent of a memory phenotype (Figure 4B).
Percentages and numbers of gp33
tetramer-positive cells were also stronglydecreased in deficient mice 5 weeks and 3 months postinfection
(Figures 4B and 4C; data not shown). At this time, we could not
detect cells capable of producing effector cytokines in response
to a cocktail of LCMV peptides in miRNA-155 ablated mice,
confirming the loss of most virus-specific Mir155/ CD8+
T cells and ruling out TCR downregulation that may appear as
tetramer-negative T cells (Figure 4E; data not shown). Whereas
about 50% of WT cells remained positive for PD-1, associated
with T cell exhaustion, PD-1 was barely detectable onMir155/
CD8+ T cells 5 weeks after infection (Figure 4C). Importantly,
virus titers were elevated 5 weeks and 2 months postinfection
in miRNA-155 ablated mice (Figure 4D; data not shown). Finally,
WT but not miRNA-155 ablated mice showed symptoms of
immunopathology such as shivering, hunching, and weight
loss, suggesting a lower inflammatory response in the absence
of miRNA-155 (Figure 4F; data not shown). These data demon-
strate an important role of miRNA-155 in maintenance and sur-
vival of CD8+ effector T cells, as well as virus control in chronic
virus infections.
Figure 5. miRNA-155 Is Crucial for the CD8+
T Cell Response to Peptide Vaccination and
Tumor Challenge
(A) Congenically marked OT-1 and polyclonal
CD8+ T cells from WT or Mir155/ backgrounds
were transferred into WT hosts, which were
immunized with OVA peptide and CpG in IFA.
Shown is the ratio of antigen-specific versus
polyclonal cells in the draining lymph nodes 4 days
later. Symbols represent individual mice, and the
line is the mean ± SEM.
(B) Ratio of blood WT and Mir155/ OT-1 CD8+
T cells cotransferred into WT hosts, which were
immunized as in (A) on day 7. Symbols represent
individual mice, and the line is the mean ± SEM.
Data from one out of two (A) to three (B) inde-
pendent experiments are pictured.
(C and D) Upon adoptive transfer of WT or
Mir155/ OT-1 cells, mice were engrafted with
B16 melanoma cells expressing OVA and immu-
nized 1 week later. Tumor growth (C) and survival
(D) are pictured (n = 5–9 mice per group, data from
one out of two independent experiments) dis-
played as mean ± SEM.
(E and F) TCR transgenic pmel CD8+ T over-
expressing miRNA-155 or control scrambled
miRNA were transferred into B16 tumor-bearing
mice and (E) tumor growth and (F) survival of mice
are shown from one representative out of two
experiments with five to eight mice per group
displayed as mean ± SEM. Also see Figure S3.
Immunity
miRNA-155 Drives the CD8+ T Cell ResponsemiRNA-155 Expression in CD8+ T Cells Is Crucial for
Efficient Immunization and Cancer Immunotherapy
Becausewe observed an important role of miRNA-155 to sustain
CD8+ T cell responses to chronic infection, we looked at the
impact of miRNA-155 on CD8+ T cell-dependent antitumor
immunity, which requires robust CD8+ T cell responses. We
examined the role of miRNA-155 in CD8+ T cells for vaccination,
a clinically relevant setting characterized by limited adjuvant-
induced inflammation. Polyclonal and OVA-specific OT-1 CD8+
T cells (either WT or Mir155/) were cotransferred into WT
mice before immunization with OVA peptide adjuvanted with
IFA and CpG-ODNs. While the ratio of WT OT-1 to polyclonal
cells strongly increased following immunization, there was only
a minor increment in the ratio of Mir155/ OT-1 to polyclonal
WT cells (Figure 5A). We next cotransferred OT-1 cells from
both WT and Mir155/ backgrounds into WT mice before
immunization. WT andMir155/ cells were found in similar pro-
portions indicating a comparable survival after adoptive transfer.
Following immunization, however, WT cells accumulated more
efficiently thanMir155/ cells (Figure 5B), whereas upregulation
of CD44 and the proportion of cells producing IFN-g were com-
parable (Figures S3A and S3B). Now we were interested to seeImmunity 38, 742–7whethermiRNA-155would also be critical
for tumor control by CD8+ T cells and
engrafted B16 melanoma upon transfer
of naive WT or Mir155/ OT-1 T cells
and therapeutic vaccination 1 week later.
Compared to WT, Mir155/ CD8+
T cells were less effective in inhibitingtumor growth and ensuring the survival of tumor-challenged
mice (Figures 5C and 3D). Given the inability of T cells to expand
and control tumor growth in the absence of miRNA-155, we
hypothesized that enforcing miRNA-155 expression would
augment theantitumor activity ofCD8+Tcells. Pmel-1 TCR trans-
genic CD8+ T cells specific for themelanoma antigen gp100were
transduced with a retrovirus encoding miRNA-155 or scrambled
miRNA and adoptively transferred into tumor-bearing mice in
conjunction with gp100 vaccination and IL-2. There were no
phenotypic differences between control andmiRNA-155 overex-
pressing T cells prior to adoptive transfer (Figure S3C). However,
overexpression of miRNA-155 greatly enhanced the antitumor
responses compared to scrambled miRNA control (Figure 5E).
Notably, 80% of mice receiving miRNA-155 transduced T cells
survived for over 60 days, whereas all mice treated with control
cells or left untreated had to be euthanized after less than
40 days due to tumor size (Figure 5F). Taken together, these re-
sults show that upon vaccination,Mir155/ CD8+ T cells differ-
entiated into effector cells but failed to accumulate in normal
numbers. Consequently, the antitumor response was strongly
dependent on miRNA-155 and could be therapeutically boosted
by enforced miRNA-155 expression.53, April 18, 2013 ª2013 Elsevier Inc. 747
Figure 6. SOCS-1 and miRNA-155 Modulate the Antiviral CD8+ T Cell Response and Cytokine Signaling
(A) SOCS-1mRNA concentrations weremeasured upon LCMVWE infection in purified effector (CD44hiCD62Llo) WT andMir155/ splenic CD8+ T cells by qPCR
relative to naive CD8+ T cells from noninfected mice.
(B and C) Regulation of SOCS-1 by miRNA-155 in naive CD8+ T cells from WT and miRNA-155 deleted mice, as well as after retroviral transfection with miRNA-
155 overexpressing or control vectors, was tested by (B) qPCR (shown as relative to b-actin) and (C) immunoblot.
(D) Naive or effector T cells from LCMV-infected mice were stimulated with indicated cytokines, and pSTAT5 was measured by flow cytometry.
(E) WT andMir155/ T cells were transduced with control or shSOCS-1 lentivirus and pSTAT5 response to IL-2 is shown. The table gives the percentages of MFI
normalized to the MFI measured in WT sh-control cells set to 100%. Representative data from two (A–C) to three (D and E) experiments are pictured as mean ±
SEM. Also see Figure S4.
Immunity
miRNA-155 Drives the CD8+ T Cell ResponseTargeting of SOCS-1 by miRNA-155 in Effector CD8+
T Cells Enables Cytokine Responsiveness and
Accumulation
miRNA-155 has been shown to regulate gc chain cytokine
signaling by targeting SOCS-1 expression (D’Souza and Lefran-
c¸ois, 2003; Lu et al., 2009; Wang et al., 2010). We assessed748 Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc.SOCS-1 regulation in splenic effector CD44+CD62L–CD8+
T cells during the response to acute LCMV infection of WT and
Mir155/ mice. We found that both WT and Mir155/ CD8+
T cells downregulated SOCS-1 on days 6 and 8 compared to
CD62L+CD44– naive CD8+ T cells from noninfected mice (Fig-
ure 6A). To more directly test whether SOCS-1 was regulated
Figure 7. SOCS-1 Limits the CD8+ T Cell
Response to Virus and Cancer
(A) TCR transgenic P14 CD8+ T cells over-
expressing SOCS-1 (P14xSOCS-1) or not were
adoptively transferred before LCMV WE infection.
Data show the percentage of transferred cells in
the lymphocyte gate at days 6, 7, and 8 post-
infection as mean ± SEM.
(B) Apoptotic cells within P14 T cells 7 days after
infection. Symbols represent single mice, and the
line is the mean.
(C and D) TCR transgenic pmel CD8+ T cells
were transduced with a retrovirus encoding
for a scrambled control or shSOCS-1 mRNA
and adoptively transferred into tumor-bearing
mice. (C) Absolute numbers of donor CD8+
T cells were determined in spleen at days 4 to
6 after adoptive transfer and (D) tumor size of
mice was monitored. Data are from one repre-
sentative out of two independent experiments
with two (C) to five mice (D) per group and
displayed as mean ± SEM. Please also see
Figure S5.
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miRNA-155 Drives the CD8+ T Cell Responseby miRNA-155, we measured SOCS-1 mRNA in WT and
Mir155/ CD8+ T cells, as well as in cells overexpressing
miRNA-155 or scrambled control miRNA. We found that the
amounts of SOCS-1 transcripts were inversely related to the
cellular content of miRNA-155, with the highest concentration
of SOCS-1 in Mir155/ cells and the lowest in miRNA-155
transduced cells (Figure 6B). These results were further
confirmed at the protein level, indicating that miRNA-155 is a
critical regulator of SOCS-1 translation in CD8+ T cells (Fig-
ure 6C). To test whether the loss of miRNA-155 impaired gc
chain cytokine signaling in CD8+ T cells by upregulating
SOCS-1, we compared STAT5 phosphorylation in response to
IL-2, IL-7, or IL-15 in WT and Mir155/ cells. Stimulation of
naive and effector CD8+ T cells isolated 8 days after LCMV
infection resulted in a limited phosphorylation of STAT5 in
miRNA-155 ablated cells, demonstrating an impaired cytokine
signaling (Figure 6D). Diminished STAT5 phosphorylation was
not due to differential expression of the cytokine receptor
chains CD25, CD122, CD127, or CD132 (Figure S4). To further
investigate whether the impaired cytokine signaling was depen-
dent on the higher SOCS-1 concentration in Mir155/ CD8+
T cells, we transduced WT and Mir155/ CD8+ T cells with
control or shSOCS-1 lentivirus. Although in vitro activation of
T cells diminished the impact of miRNA-155 on cytokine
signaling, we consistently detected a rescue of pSTAT5 gener-
ation in shSOCS-1 transfected Mir155/ cells (Figure 6E).
Interestingly, baseline pSTAT5 expression was already higher
in WT than inMir155/ cells without additional IL-2 stimulation.
The difference between WT and Mir155/ cells was still
apparent with intermediate but disappeared with high IL-2 con-
centrations, demonstrating that saturating amounts of IL-2
overcome the miRNA-155 and SOCS-1-dependent inhibitionImmunity 38, 742–7of cytokine signaling, as shown for regu-
latory T cells (Lu et al., 2009). Together,
these results demonstrate a dynamicand differentiation-dependent regulation of SOCS-1 during
the response to LCMV and suggest that Mir155/ CD8+
T cells have impaired cytokine signaling due to increased
SOCS-1.
SOCS-1 Restrains CD8+ T Cell Responses to Virus and
Cancer
To test whether increased SOCS-1 expression recapitulated the
impaired antigen-driven expansion of Mir155/ CD8+ T cells,
we adoptively transferred SOCS-1 transgenic or WT P14 CD8+
T cells into congenicmice prior to infection with LCMVWE strain.
The expansion of SOCS-1 transgenic P14 T cells in blood and
spleen was reduced compared to P14 WT cells (Figure 7A;
data not shown). Whereas effector phenotype, granzyme B,
and cytokine production were not impaired (Figures S5A–S5C),
we detected enhanced apoptosis of SOCS-1-overexpressing
cells (Figure 7B), thus phenocopying Mir155/ CD8+ T cells
(Figures 2 and 3; Figure S2). To test whether suppression of
SOCS-1 could be therapeutically exploited to enhance the
CD8+ T cell antitumor response, we adoptively transferred
Pmel CD8+ T cells transduced with shSOCS-1 into tumor-
bearing mice. SOCS-1 depletion by the construct was verified
by immunoblot analysis (Figure S5D). An increased expansion
of cells expressing shSOCS-1 was detected in the spleen on
day 4 compared to control (Figure 7C), associated with profound
tumor regression in mice that received shSOCS-1 transduced
cells compared to untreated mice or mice treated with control
cells (Figure 7D). Together, these results demonstrate that
SOCS-1 is negatively regulating the effector CD8+ T cell
response to virus and cancer and highlight the importance of
SOCS-1 downregulation by miRNA-155 for efficient CD8+
T cell responses.53, April 18, 2013 ª2013 Elsevier Inc. 749
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We have shown that miRNA-155 expression is essential for
optimal CD8+ T cell responses toward virus infection, vaccina-
tion, and cancer. Interestingly, the phenotype of Mir155/
CD8+ T cells was similar to Dicer-deficient CD8+ T cells (Zhang
and Bevan, 2010), suggesting that miRNA-155 is an important,
likely nonredundant miRNA for CD8+ effector T cells. Recently,
we and others found differential miRNA-155 expression associ-
ated with discrete differentiation stages in CD8+ T cells (Almanza
et al., 2010; Salaun et al., 2011; Wu et al., 2007). Here, we
showed that miRNA-155 is highly upregulated in effector CD8+
T cells responding to viral infection but at intermediate concen-
tration in memory cells. This dynamic modulation of miRNA-
155 raises the question of the nature of the regulating factors
that are involved. miRNA-155 is induced by NF-kB-dependent
factors (Kluiver et al., 2007) and AP-1 downstream of B and
T cell receptors (Haasch et al., 2002; Yin et al., 2008). Interest-
ingly, we observed that miRNA-155 expression was proportional
to the strength of TCR signaling, suggesting that miRNA-155
provides competitive fitness to the most avid antigen-specific
CD8+ T cells.
Whereas others reported a disadvantage of Mir155/ naive
CD8+ T cells in bone-marrow chimeras (Lu et al., 2009), we found
that expansion and long-term survival of naive Mir155/ CD8+
T cells transferred into lymphopenic hosts were not different
from WT cells. miRNA-155 was crucial for effector CD8+ T cell
proliferation and survival during the peak of LCMV infection,
but it did not influence cell survival upon antigen clearance. In
contrast to the reported role of miRNA-155 in other immune
cells, CD8+ T cells were not affected in effector functions such
as killing or cytokine production, and miRNA-155 deleted mice
readily cleared low doses of LCMV. Interestingly, we detected
an impaired generation of virus-specific central memory CD8+
T cells because most Mir155/ cells displayed a terminally
differentiated phenotype. Whether this was due to a lack of
CD4+ T cell help (Janssen et al., 2003; Shedlock and Shen,
2003), lower cytokine signaling due to higher SOCS-1 expres-
sion, and/or additional miRNA-155 targets will be subject of
further investigation. In contrast to low-dose LCMV infection,
we found that virus-specific Mir155/ effector cells disap-
peared during chronic LCMV infection by using high doses of
clone 13. Under these conditions, WT CD8+ T cells undergo pro-
gressive attrition and display an ‘‘exhausted’’ phenotype with
impaired effector functions and high PD-1 expression (Jin
et al., 2010; Mueller and Ahmed, 2009; Wherry et al., 2003).
We hypothesize that miRNA-155 is key for the survival of
effector CD8+ T cells in conditions of long-term exposure to
antigen and inflammation as found in chronic viral infections or
cancer. Consistent with the impaired virus control, lack of
miRNA-155 protected from LCMV-induced severe immunopa-
thology, which is in line with reports demonstrating a pivotal
role of miRNA-155 in autoimmune inflammation (Murugaiyan
et al., 2011; O’Connell et al., 2010). With regard to T cell survival,
miRNA-155 was shown to inhibit caspase 3 activity in Jurkat
T cells (Ovcharenko et al., 2007) and FADD expression in macro-
phages (Tili et al., 2007). Whether the increased apoptosis of
Mir155/ CD8+ T cells was due to such mechanisms remains
to be determined.750 Immunity 38, 742–753, April 18, 2013 ª2013 Elsevier Inc.In line with our results in virus infection, we demonstrate a
central role for miRNA-155 in tumor-specific CD8+ T cells. First,
the efficient accumulation of CD8+ T cells by vaccination with
adjuvanted peptide required intrinsic miRNA-155 function, reca-
pitulating our observations in LCMV infection. More importantly,
Mir155/ effector cells were severely impaired in their ability to
curb tumor growth. Because these cells acquired full effector
functions independently of miRNA-155, the different tumor con-
trol was likely due to defect in the magnitude of tumor-specific
T cells or to higher susceptibility to the suppressive tumor-micro-
environment (Klebanoff et al., 2011). Conversely, overexpression
of miRNA-155 greatly increased tumor killing by WT CD8+
T cells. This indicates that tumor-specific CD8+ T cell activity is
directly dependent on miRNA-155 expression.
The accumulation of effector CD8+ T cells is influenced by the
cytokine milieu; e.g., their initial expansion is promoted by gc
cytokines, which signaling is regulated by SOCS-1 (Cornish
et al., 2003). More specifically, CD8+ effector cell accumulation
in the LCMV response is reduced if cells lack gc signaling (Dec-
aluwe et al., 2010). Interestingly, IL-2 was found to be critical for
the maintenance of effector CD8+ T cells in chronic LCMV infec-
tions (Bachmann et al., 2007). Here we show thatmiRNA-155 en-
hances cytokine signaling in CD8+ T cells by targeting SOCS-1.
Consequently, Mir155/ naive and effector CD8+ T cells failed
to mount physiologic levels of pSTAT5 in response to gc cyto-
kines. In line with in vitro experiments using CD4+ T cells (Lu
et al., 2009), we observed strong and transient in vivo downregu-
lation of SOCS-1 mRNA in virus-specific CD8+ T cells at day 6 of
the response. Interestingly, this occurred in a partially miRNA-
155 independent manner, whereas SOCS-1 protein concentra-
tions of naive and effector CD8+ T cells were found to be clearly
dependent on miRNA-155. Moreover, we did not detect an
impact of miRNA-155 on pSTAT5 in response to IL-2 in the early
effector response in vivo as well as after in vitro priming (data
not shown), whereas the effect was pronounced in naive and
late effector cells. This suggests a miRNA-155 independent
mechanism allowing full cytokine signaling early in the effector
response, whereas miRNA-155 is modulating cytokine signaling
in naive and late effector cells, promoting their accumulation and
survival. Interestingly, at the peak of the response, effector CD8+
T cells are reportedly dependent on IL-2 and IL-15 for sustained
expansion (D’Souza and Lefranc¸ois, 2003; Sanjabi et al., 2009).
We were able to confirm a SOCS-1-dependent inhibition of
cytokine signaling in Mir155/ T cells by transduction with a
shSOCS-1 lentivirus in in vitro experiments. Although the formal
proof that loss of SOCS-1 inMir155/CD8+ T cells in vivowould
restore their function remains to be shown, the observed rescue
of STAT5 phosphorylation in Mir155/ cells back to WT levels
suggests that suppression of SOCS-1 in WT, but not Mir155/
T cells, caused the differences in pSTAT5 signaling. This
hypothesis was further supported by our observation that
virus-specific, SOCS-1 transgenic CD8+ T cells fully differenti-
ated but failed to accumulate to normal numbers at the peak of
the LCMV response, which mirrors the phenotype of Mir155/
T cells and identifies SOCS-1 as an important regulator of
CD8+ T cell responses in vivo. Conversely, suppression of
SOCS-1 in tumor-specific cells increased the accumulation
of transferred cells and subsequently was highly therapeutic
in limiting growth of established melanoma. Thus, although a
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gested before (Chong et al., 2003; Cornish et al., 2003; Davey
et al., 2005; Marine et al., 1999; Palmer and Restifo, 2009), we
here demonstrate a cell-intrinsic role of SOCS-1 in responses
to virus and cancer. Our results of the highly dynamic regulation
of SOCS-1 expression in vivo and the strong impact of SOCS-1
alterations in responses to virus and tumor suggests that a major
part of the effects caused in CD8+ T cells by miRNA-155 deletion
are due to increased SOCS-1 expression.
In summary, the results presented here identified a crucial cell-
intrinsic role of miRNA-155 and its target SOCS-1 in effector
CD8+ T cells and demonstrated that this miRNA is required for
an optimal CTL response to both virus and tumor. Moreover,
miRNA-155 overexpression in tumor-specific CD8+ T cells
substantially increased their potency, thus providing strong
evidence for a clinical potential in the context of therapeutic
adoptive T cell transfer.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6mice were fromHarlan.Mir155–/– andRag2–/–Il2rg–/–, TCR transgenic
OT-I, and P14 mice bearing a transgenic TCR-specific for Kb/OVA257–264 or
LCMV Db/GP33–41 MHC-I/peptide complexes, respectively, were from Jack-
son and were bred under specific pathogen-free conditions. P14xSOCS-1
transgenic (Seki et al., 2007) and Pmel-1 transgenic mice expressing a TCR-
specific for an H-2Db-restricted CD8+ T cells epitope from the murine mela-
noma tumor antigen gp10025–33 or human gp10025–33 have been described
(Overwijk et al., 2003). All animal experiments were conducted with the
approval of the Lemanic Animal Facility Network (RESAL), NCI (protocol SB-
126) or NIAID (protocol LI-10) Animal Use and Care Committees.
Quantitative PCR
Total RNA from subsets was extracted with the miRNAVana kit (Ambion), and
mature microRNAs (miRNA-155 and controls RNU44 and snoRNA202) were
reverse transcribed with TaqMan RT MicroRNA Kit (Applied Biosystems)
and amplified by using Universal Fast Start Rox Probe Master Mix (Roche)
and microRNA assay kits in 384-well plates (Applied Biosystems) on an ABI
Prism 7900 HT device (Applied Biosystems). RT-PCR for Socs1 was per-
formed with primers from Applied Biosystems. Gene expression was calcu-
lated relative to G6PDX.
In Vitro Priming with Dendritic Cells
T cells were purified from lymphoid tissues by using anti-CD8a beads (Miltenyi)
and cocultured with peptide pulsed Mir155/ DC. In competition experi-
ments, equal numbers of WT and Mir155/ OT-1 CD8+ T cells were cocul-
tured with WT DC.
Differential Stimulation of Human CD8+ T Cells and Microarray
Human T cells transduced with NY-ESO-1 TCR variants (Schmid et al., 2010)
were stimulated with 0.01 mg/ml (for miRNA-155 quantification) or 0.002 mg/ml
(for BIC microarray) NY-ESO-1157–165 multimer. BIC quantification was done
by Miltenyi Biotec.
LCMV Infection
Mice were infected intravenously with 200 pfu of the WE strain or 2 3 106 pfu
clone 13 of LCMV. Cell counts in blood were performed with TrueCount tubes
according to the manufacturer’s instructions (BD). Viral titrations were per-
formed by a standard plaque assay.
Cytokine and Cytotoxicity Assays
Splenocytes were stimulated with indicated peptides or a mix of LCMV pep-
tides (gp33, gp70, gp92, gp118, gp276, np166, np205, np235, np396) at
5 mM each or PMA (50 ng/mL) and Ionomycin (500 ng/mL) in the presence of
GolgiStop (BD PharMingen) for analysis in flow cytometry. Cytolytic activitywas assessed by using the chromium release assay with EL4 pulsed with
1 mM GP33–41 peptide and measured with a TopCount reader (Canberra
Packard).
Adoptive Cell Transfers
Before LCMV infection, CD8+ T cells were purified by magnetic beads sorting
(Miltenyi Biotec) and 1 3 106 purified CD8+ T cells were injected into the tail
vein. In the P14xSOCS-1 experiments, 33 104 cells were injected normalized
to gp33 tetramer-positive populations. For vaccination and tumor challenge,
OT-1cells were purified and 1 3 106 cells were injected intravenously 3 days
before subdermal injection of 1 3 105 B16 melanoma cells expressing
OVA. Seven days later, mice were vaccinated subcutaneously with 25 mg
OVA257–264 peptide and 50 mg CPG-ODN in PBS.
T Cell Transduction and Transfers into Tumor Bearing Mice
Pmel CD8+ T cells were stimulated with anti-CD3 (2mg/ml) and anti-CD28
(1mg/ml) for 24 hr, transduced with retrovirus expressingmiRNA-155 or scram-
bled miRNA, and expanded for 4 days. To knock down SOCS-1, we trans-
duced pmel CD8+ T cells 2 days after stimulation with lentivirus expressing
shSOCS-1 or empty vector and selected in puromycin from days 4 to 7 prior
to transfer into tumor-bearing hosts. We injected 107 cells (miRNA-155 exper-
iments) or 106 (shSOCS-1 experiments) intravenously into mice bearing B16
tumor in conjunction with 2 3 107 pfu rvvhgp100 and IL-2 (6X6e4 cu). In
shSOCS-1 experiments, mice were sublethally irradiated prior to cell transfer.
Tumor volumes were plotted as the product of perpendicular diameters. For
rescue of pSTAT5 in miRNA-155 cells, WT and Mir155/ CD8+ T cells were
transduced with lentivirus encoding shSOCS-1 or control sh and cultured for
1 week with IL-2 or IL-15 (R&D systems, 20 ng/ml) before cytokine stimulation
(vector sequences upon request).
Flow Cytometry and pSTAT5 Measurements
Cells were stained with antibodies of the indicated specificities (eBioscience)
or H-2 Db/peptide-loaded MHC. PD-1 PE-Cy7 antibody was from Biolegend.
For detection of pSTAT5, cells were stimulated with indicated cytokines
(R&D systems) for 18 min and fixed with 0.5% formaldehyde in PBS for
15 min. Upon washing in medium containing 10% FCS, cells were permeabi-
lized in 80% methanol for 20 min, washed, and stained with pSTAT5 antibody
(BD Biosciences) and additional markers (eBiosciences). Labeled cells were
analyzed on LSR-II (Becton Dickinson).
Immunoblot
Cells were lysed (Cell Signaling Technologies) and immunoblotting was per-
formed by using Bio-Rad TGX reagents and protocols on nitrocellulose paper,
incubated with antibodies against SOCS-1 (Lifespan Biosciences [Figure 6C]
or Imgenex [Figure S6]) and with appropriate HRP-conjugated secondary
antibodies (Cell Signal Technologies). Blots were developed by using chemilu-
minescence (Pierce), gel images were captured with Gel Doc XRS (Bio-Rad),
and densitometry was evaluated using Quantity One software (Bio-Rad).
Proliferation and Apoptosis Assay
Mice were injected intraperitoneally with 200 mg BrdU, and proliferation was
measured in spleen cells 1 hr (P14xSOCS-1 experiments) or 4 h (miRNA-155
experiments) later by staining with anti-BrdU and anti-ki67+ antibodies.
Apoptotic cells were detected by staining splenocytes for AnnexinV upon
1 hr in vitro incubation at 37C (all BD PharMingen).
Statistics
The two-tailed Student’s t test was used to compare two groups; multiple
groups’ comparisons were performed with one-way ANOVA corrected with
Bonferroni’s multiple-comparison test factor. Statistical survival differences
in the tumor experiments were analyzed with the log rank test. Statistical
significance is displayed as *p < 0.05, **p < 0.01, and ***p < 0.001. Data are dis-
played as mean and SEM if not indicated otherwise.
SUPPLEMENTAL INFORMATION
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Figure S1. Early Expression of BIC Is Dependent on TCR Affinity, Related to Figure 1 
Expression fold-changes (0-6h) in the levels of BIC (pre-miR-155) non-coding RNA in the 
panel of primary human CD8
+
 T cells transduced with NY-ESO-1-specific TCRs of 
increasing affinity following TCR stimulation with NY-ESO-1157-165 multimers. Data are 
from one microarray experiment. 
 
 
  
Supplemental Figure 2 related to Figure 2 A-C 
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Figure S2. miR-155 Independent Acquisition of Effector Functions but Defective 
Memory Formation, Related to Figure 2 
(A) Differentiation markers on naïve, or gp33 and np396 tetramer positive, virus specific 
CD8
+
 T cells from blood of naïve or day 8 LCMV WE infected wild type (WT) and Mir155
-/- 
mice were measured by flow cytometry.  
(B) Virus titers were determined in spleens at day 5 of infection.  
(C) Lack of virus persistence was confirmed by transferring naïve P14 T cells into mice on 
day 21 after LCMV infection. Pictured is CD44 expression of gp33-tetramer
+
 host and donor 
P14 cells at 3 days after the transfer.  
(D) Production of indicated cytokines from gp33 tetramer
+
CD8
+
 splenocytes after in vitro 
restimulation with PMA/Ionomycin at day 8 post infection.  
(E) Cytotoxic activity of gp33 tetramer
+
CD8
+
 T cells at day 8 after LCMV infection was 
determined by chromium release assay using peptide-pulsed target cells. Representative 
results from one out of two experiments are shown.  
(F) Phenotype and cytokine production (upon peptide restimulation) of splenic LCMV 
specific, gp33 tetramer
+
CD8
+
 T cells from infected wild type (WT) and Mir155
-/-  
mice was 
monitored 3 month upon infection. Points are representing single mice and the line is the 
mean (B, C). Representative results of one out of three independent experiments with three to 
five mice are pictured. 
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Figure S3. Acquisition of Effector Phenotype and IFN- Production Upon Vaccination 
Is Independent of miR-155, Related to Figure 5 
Wild type (WT) and Mir155
-/- 
OT-1 cells were transferred into WT mice before vaccination. 
(A) Upregulation of CD44 as well as (B) IFN- production by respective OT-1 cells was 
measured in draining lymph nodes on day 4 after vaccination upon restimulation. Data are 
from one representative out of two experiments with three to five mice per group.  
(C) GFP marker positive scrambled miR control and miR-155 transduced cells were stained 
for the indicated activation markers and cytokine receptors before injection into tumor 
bearing mice.  
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 Figure S4. miR-155 Does Not Affect Cytokine Receptor Expression in Naïve CD8
+
 T 
Cells, Related to Figure 6 
Naïve (CD44
low
CD62L
high
) CD8
+
 T cells from untreated wild type (WT) or Mir155
-/- 
mice 
were stained for indicated cytokine receptors. Representative results from one out of two 
experiments with three to five mice are shown. 
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Figure S5. Elevated SOCS-1 Expression Does not Affect CD8
+
 Effector Phenotype. 
Downregulation of SOCS-1 by Retroviral shSOCS-1 Transduction, Related to Figure 7 
P14 and P14xSOCS-1 transgenic T cells were transferred into wild type mice before infection 
with LCMV WE. Expression of (A) activation markers on day 8 and (B) Granzyme B on day 
7 was monitored on P14 cells from spleen and displayed as mean +/- SEM.  
(C) Cytokine production of splenic P14 T cells was measured upon in vitro stimulation with 
gp33 peptide. Representative data from one out of two experiments (N= 3 to 4) are pictured 
and the line in the last panel represents the mean.  
(D) Inhibition of SOCS-1 expression by two different shSOCS-1 constructs was validated by 
Immunoblot on transduced T cells. shSOCS-1-21 was used for rescue of pSTAT5 generation 
in Mir155
-/- 
cells (Figure 6D). 
 
